Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer.
RM26
albumin-binding domain
gastrin-releasing peptide receptor
gastrin-releasing peptide receptors (GRPR) antagonist
prostate cancer
targeted therapy
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
16 Oct 2020
16 Oct 2020
Historique:
received:
28
09
2020
revised:
12
10
2020
accepted:
14
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
The targeting of gastrin-releasing peptide receptors (GRPR) was recently proposed for targeted therapy, e.g., radiotherapy. Multiple and frequent injections of peptide-based therapeutic agents would be required due to rapid blood clearance. By conjugation of the GRPR antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH
Identifiants
pubmed: 33081166
pii: pharmaceutics12100977
doi: 10.3390/pharmaceutics12100977
pmc: PMC7594083
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : VINNOVA
ID : 2019/00104
Organisme : Cancerfonden
ID : 2017/425
Organisme : Cancerfonden
ID : 2018/436
Organisme : Cancerfonden
ID : 19 0212 Pj 01H
Organisme : Vetenskapsrådet
ID : 2019-00986
Organisme : Vetenskapsrådet
ID : 2015-02353
Organisme : Vetenskapsrådet
ID : 2016-05207
Références
Peptides. 1991 Sep-Oct;12(5):1149-51
pubmed: 1666185
Cancer Res. 2007 Mar 15;67(6):2773-82
pubmed: 17363599
Prostate. 2014 Feb;74(2):217-24
pubmed: 24150752
Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1406-11
pubmed: 8643644
Int J Oncol. 2016 May;48(5):2124-34
pubmed: 26983776
Biopolymers. 1991 Nov;31(13):1463-70
pubmed: 1814498
J Nucl Med. 2017 Feb;58(2):293-299
pubmed: 27609789
Cells. 2018 Oct 11;7(10):
pubmed: 30314301
J Biol Chem. 1990 Jul 15;265(20):12052-8
pubmed: 2164025
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1386-96
pubmed: 20182713
Adv Exp Med Biol. 2018;1096:135-158
pubmed: 30324352
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):123-135
pubmed: 31482426
Chem Rev. 2010 May 12;110(5):2858-902
pubmed: 20415480
Gene. 2001 Feb 7;264(1):95-103
pubmed: 11245983
J Nucl Med. 2019 May;60(5):656-663
pubmed: 30552199
J Nucl Med. 2018 Jun;59(6):922-928
pubmed: 29123014
Prostate. 2009 Jul 1;69(10):1101-8
pubmed: 19343734
J Control Release. 2018 Oct 28;288:84-95
pubmed: 30172673
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136
pubmed: 28765998
Exp Mol Med. 2017 Mar 24;49(3):e306
pubmed: 28336959
Molecules. 2014 Jul 17;19(7):10455-72
pubmed: 25036155
Clin Nucl Med. 2018 Sep;43(9):663-669
pubmed: 30036253
Curr Med Chem. 2020 Mar 12;:
pubmed: 32164503
Biochem Biophys Res Commun. 1986 Nov 26;141(1):99-105
pubmed: 3801011
J Nucl Med. 2013 May;54(5):762-9
pubmed: 23492884
Bioconjug Chem. 2020 Feb 19;31(2):396-403
pubmed: 31880916
J Med Chem. 1999 Nov 18;42(23):4919-24
pubmed: 10579854
Biopolymers. 2014 May;102(3):252-9
pubmed: 24549714
Cancer Res. 1999 Mar 1;59(5):1152-9
pubmed: 10070977
J Nucl Med. 2016 Apr;57(4):557-62
pubmed: 26659347
Clin Cancer Res. 2013 Oct 1;19(19):5434-43
pubmed: 23935037
Int J Cancer. 2019 Dec 15;145(12):3347-3358
pubmed: 31077356
Prostate. 2012 Feb;72(3):318-25
pubmed: 21739464
Ann Oncol. 2007 Sep;18(9):1457-66
pubmed: 17351255
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biol Chem. 2002 Mar 8;277(10):8114-20
pubmed: 11751858
Nucl Med Biol. 2015 May;42(5):446-454
pubmed: 25684649
Protein Eng Des Sel. 2008 Aug;21(8):515-27
pubmed: 18499681
Transl Androl Urol. 2018 Oct;7(5):831-843
pubmed: 30456186
Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81
pubmed: 18279057
J Nucl Med. 2013 Jun;54(6):961-8
pubmed: 23528382